Gland Pharma’s ESOP Compensation Committee has approved the grant of 5,90,249 stock options to 124 employees under the Gland Pharma Employee Stock Options Scheme, 2025 (‘ESOP 2025’). This grant, approved on September 13, 2026, includes options priced at INR 1,461.15 and INR 1. The options vest over three years, with exercise possible within two years post-vesting.
Gland Pharma Approves Significant Stock Option Grant
Gland Pharma Limited has announced the approval of a substantial stock option grant to its employees. The ESOP Compensation Committee of the Board of Directors, in its meeting held on September 13, 2026, sanctioned the grant of 5,90,249 Employee Stock Options. These options are being issued under the Gland Pharma Employee Stock Options Scheme, 2025 (ESOP 2025).
Employee Participation and Option Details
A total of 124 employees of the company will be beneficiaries of this stock option grant. The grant is in line with the company’s commitment to incentivize and retain its workforce. The details provided indicate a two-tiered pricing strategy for these options. A significant portion of 3,89,564 options have been granted at an exercise price of INR 1,461.15, which represents 50% of the equity share’s closing price on NSE as of September 11, 2026. The remaining 2,00,685 options are priced at the face value of the equity share, INR 1.
Vesting and Exercise Period
The vesting of these stock options will occur in stages over three years. Specifically, 34% of the total granted options will vest upon completion of the first year from the vesting date, which is September 13, 2027. Subsequently, 33% will vest upon completion of the second year (September 13, 2028), and the final 33% will vest upon completion of the third year (September 13, 2029). Employees will have a maximum period of two years from the respective vesting dates to exercise their options.
Source: BSE
